Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) binding site , is exhibiting promising results in initial patient trials . Ongoing examination https://bookmarksden.com/story21544357/retatrutide-emerging-studies-and-possible-therapeutic-applications